Clinical Trials Logo

Hemophilia A clinical trials

View clinical trials related to Hemophilia A.

Filter by:
  • Approved for marketing  
  • Page 1

NCT ID: NCT03154437 Approved for marketing - Hemophilia A Clinical Trials

An Expanded Access Program of Emicizumab in Participants With Hemophilia A With Inhibitors

Start date: n/a
Phase:
Study type: Expanded Access

This open-label, multicenter expanded access program (EAP) is designed to provide emicizumab to eligible participants with hemophilia A with factor VIII (FVIII) inhibitors before it is commercially available in the United States for the indication of hemophilia A with FVIII inhibitors. Discontinuation may occur earlier if participant or physician decides to discontinue treatment or the sponsor discontinues emicizumab clinical development.